Cargando…

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol

AIM: To determine whether high triglycerides (TG) in the presence of statin‐controlled LDL‐C influence the risk of cardiovascular disease (CVD) among patients with diabetes in real‐world clinical practice. MATERIALS AND METHODS: We identified adults with diabetes from the Southern California and Pac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nichols, Gregory A., Philip, Sephy, Reynolds, Kristi, Granowitz, Craig B., Fazio, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587847/ https://www.ncbi.nlm.nih.gov/pubmed/30225881 http://dx.doi.org/10.1111/dom.13537

Ejemplares similares

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022)

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk
por: Toth, Peter P., et al.
Publicado: (2018)

Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients
por: Toth, Peter P, et al.
Publicado: (2019)

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2019)

Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high‐risk statin‐treated patients: A large administrative retrospective analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Beyond LDL-Cholesterol: The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy
por: Watson, Karol E.
Publicado: (2008)

Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides
por: Higashi, Yukihito
Publicado: (2023)

Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
por: Sakuma, Masashi, et al.
Publicado: (2022)

Triglyceride and Small Dense LDL-Cholesterol in Patients with Acute Coronary Syndrome
por: Hori, Masakazu, et al.
Publicado: (2021)

Pre-Treatment with Statins for Coronary Intervention: Pleiotropy of Statins or Effect of LDL-cholesterol Reduction?
por: Habon, Tamas, et al.
Publicado: (2016)

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol
por: Al-Sabti, Hilal, et al.
Publicado: (2022)

Beyond LDL: Understanding Triglyceride-Rich Lipoproteins to Tackle Residual Risk
por: Gugliucci, Alejandro
Publicado: (2023)

Effect of sesamin on serum cholesterol and triglycerides levels in LDL receptor-deficient mice
por: Peñalvo, José L., et al.
Publicado: (2006)

Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation
por: Kim, Kyungpil, et al.
Publicado: (2014)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol
por: Hirano, Tsutomu, et al.
Publicado: (2022)

Effects of BMI and LDL-cholesterol change pattern on cardiovascular disease in normal adults and diabetics
por: Youk, Tae Mi, et al.
Publicado: (2020)

Detection of quantitative trait loci affecting serum cholesterol, LDL, HDL, and triglyceride in pigs
por: Uddin, Muhammad Jasim, et al.
Publicado: (2011)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
por: Postmus, Iris, et al.
Publicado: (2014)

Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study
por: Wagner, Jeffrey R., et al.
Publicado: (2022)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"
por: Fazio, Sergio, et al.
Publicado: (2001)

JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs
por: Aggarwal, Dimple, et al.
Publicado: (2005)

Influence of serum total cholesterol, LDL, HDL, and triglyceride on prostate cancer recurrence after radical prostatectomy
por: Cheng, Sheng, et al.
Publicado: (2019)

Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study
por: Hansen, Malene Kærslund, et al.
Publicado: (2023)

Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines
por: Ross, Elsie Gyang, et al.
Publicado: (2016)

Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?
por: Han, Ki Hoon
Publicado: (2019)

Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol
por: Sim, Doo Sun, et al.
Publicado: (2019)

Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System
por: Lucas, Joseph E., et al.
Publicado: (2017)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
por: Jetty, Vybhav, et al.
Publicado: (2017)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023)

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)
por: Langslet, Gisle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ihqom4hhkakhhe0e6ng4q31cr7